Bernhard Heinrich

Dr. Bernhard Heinrich


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2015 in MMW - Fortschritte der Medizin
Verified
Journal Article
Closed access
PDF file
BHBernhard Heinrich
Bernhard Heinrich
OBOlaf Brudler
Olaf Brudler
MBMarkus Bangerter
Markus Bangerter

28 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Marcus SchmidtMarcus Schmidt
Marcus Schmidt
THTobias Hesse
Tobias Hesse
OHOliver Hoffmann
Oliver Hoffmann
BHBernhard Heinrich
Bernhard Heinrich
TPTjoung Won Park-Simon
Tjoung Won Park-Simon
Christian JackischChristian Jackisch
Christian Jackisch
Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.

17 December 2020 in MMW - Fortschritte der Medizin
Verified
Journal Article
Closed access
BHBernhard Heinrich
Bernhard Heinrich

10 June 2021 in MMW - Fortschritte der Medizin
Verified
Journal Article
Closed access
BHBernhard Heinrich
Bernhard Heinrich

4 December 2008
Verified
Journal Article
Closed access
GRG Reimer
G Reimer
OBO Brudler
O Brudler
BHBernhard Heinrich
Bernhard Heinrich
MBM Bangerter
M Bangerter

30 September 2004
Verified
Journal Article
Closed access
MBM Bangerter
M Bangerter
BHBernhard Heinrich
Bernhard Heinrich
OBO Brudler
O Brudler